IPR decision: Oct. 05, 2020
| AIA Review # | Filing Date | Institution Date | Petitioner | Patent | Respondent | Final Written Decision |
| IPR2016-01479 | 07/22/2016 | 02/15/2017 | Par Pharmaceutical, Inc*. | 9,006,224 | Novartis AG | Challenged claims patentable |
*This proceeding as initially filed named Par Pharmaceutical, Inc. as the sole Petitioner. Argentum Pharmaceutical LLC was joined as a party to this proceeding via a Motion for Joinder in IPR2017-01063; West-Ward Pharmaceuticals International Limited was joined as a party via a Motion for Joinder in IPR2017-01078. Subsequently, Par and West-Ward separately requested termination of their participation in the proceeding pursuant to settlement. Argentum Pharmaceutical LLC is the sole remaining Petitioner.
US 9,006,224 (Novartis AG; Exp: 07/01/2028)
1. A method for treating pancreatic neuroendocrine tumors, comprising administering to a human subject in need thereof a therapeutically effective amount of 40-O-(2-hydroxyethyl)-rapamycin as a monotherapy and wherein the tumors are advanced tumors after failure of cytotoxic chemotherapy.
Leave a Reply